Systemic Antifungal Therapy
Amphotericin B (AmB) (n=8, 24%) was the empirical antifungal treatment of choice until 2010, when it was replaced mainly by liposomal amphotericin B (ambisome) (n=13, 38%). Novel antifungals, posaconazole and isavuconazole, have been employed as additional treatment options in our institution since 2008 and 2017, respectively. Antifungal treatment was adjusted following the identification of infectious agent.